financetom
Business
financetom
/
Business
/
PhonePe hits 250 mn user mark, registers 925 mn transactions in October
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PhonePe hits 250 mn user mark, registers 925 mn transactions in October
Nov 2, 2020 4:28 AM

Flipkart-owned fintech platform PhonePe on Monday said it has crossed the 250 million registered user milestone. The company reported over 100 million monthly active users (MAU) and 2.3 billion app sessions in October, a statement said. ”PhonePe had a record month in October, processing 925 million transactions – its highest so far – with an annual TPV (total payment volume) run rate of USD 277 billion. PhonePe also processed 835 million UPI transactions in October, for a market-leading share of over 40 percent,” it added.

Sameer Nigam, CEO and founder of PhonePe, said the company has set a target of crossing 500 million registered users by December 2022. ”In line with our brand ethos of ’Karte Ja. Badhte Ja’, we continue to launch new and innovative products for every strata of Indian society, as well as enable digital payment acceptance across every merchant in every village and town in India,” he added.

PhonePe – which competes with the likes of Paytm, MobiKwik and Google Pay – allows users to send and receive money, recharge mobile and make utility payments as well as buy gold and make investments. It had also launched its ’Switch’ platform that allows customers can place orders on over 220 apps including Ola, Myntra, IRCTC, Goibibo, RedBus and Oyo.

Also Read

: Paytm Postpaid aims to double postpaid service users to 1.5 cr by March 2021

PhonePe is accepted at 13 million merchant outlets across 500 cities nationally.

First Published:Nov 2, 2020 1:28 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Usana Health Sciences Insider Sold Shares Worth $257,022, According to a Recent SEC Filing
Usana Health Sciences Insider Sold Shares Worth $257,022, According to a Recent SEC Filing
Mar 11, 2024
02:32 PM EDT, 03/11/2024 (MT Newswires) -- Walter Noot, COO, on March 08, 2024, sold 5,240 shares in Usana Health Sciences ( USNA ) for $257,022. SEC Filing: https://www.sec.gov/Archives/edgar/data/896264/000089626424000113/xslF345X03/wk-form4_1710181361.xml Price: 49.05, Change: +0.47, Percent Change: +0.97 ...
Usana Health Sciences Insider Sold Shares Worth $539,539, According to a Recent SEC Filing
Usana Health Sciences Insider Sold Shares Worth $539,539, According to a Recent SEC Filing
Mar 11, 2024
02:33 PM EDT, 03/11/2024 (MT Newswires) -- Kevin Guest, Executive Chairman of the Board, on March 11, 2024, sold 11,011 shares in Usana Health Sciences ( USNA ) for $539,539. Following the Form 4 filing with the SEC, Guest has control over a total of 10,491 shares of the company, with 10,491 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/896264/000089626424000115/xslF345X03/wk-form4_1710181559.xml Price: 49.12,...
Cbl & Associates Properties Insider Sold Shares Worth $370,501, According to a Recent SEC Filing
Cbl & Associates Properties Insider Sold Shares Worth $370,501, According to a Recent SEC Filing
Mar 11, 2024
02:22 PM EDT, 03/11/2024 (MT Newswires) -- Stephen D Lebovitz, Director, CEO, on March 07, 2024, sold 15,893 shares in Cbl & Associates Properties ( CBL ) for $370,501. Following the Form 4 filing with the SEC, Lebovitz has control over a total of 404,018 shares of the company, with 403,696 shares held directly and 322 controlled indirectly. SEC Filing:...
Moderna, Merck to Begin Phase 2/3 Study of V940 Plus Pembrolizumab in Skin Cancer
Moderna, Merck to Begin Phase 2/3 Study of V940 Plus Pembrolizumab in Skin Cancer
Mar 11, 2024
02:26 PM EDT, 03/11/2024 (MT Newswires) -- Moderna ( MRNA ) and Merck ( MRK ) will start a phase 2/3 study of cancer vaccine V940, or mRNA-4157, plus pembrolizumab in patients with cutaneous squamous cell carcinoma, a form of skin cancer, according to a government trial website. The study is expected to begin on April 18, according to ClinicalTrials.gov....
Copyright 2023-2026 - www.financetom.com All Rights Reserved